Thyroid transcription factor‐1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma

In the current study, the authors investigated whether thyroid transcription factor‐1 (TTF‐1) expression is correlated with the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and whether it stratifies patients with stage I lung adenocarcinoma with respect to disease recurrence.

[1]  I. Wistuba,et al.  Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome , 2012, Cancer.

[2]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Prasad S Adusumilli,et al.  A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma , 2012, Modern Pathology.

[4]  R. Chappell.  Competing Risk Analyses: How Are They Different and Why Should You Care? , 2012, Clinical Cancer Research.

[5]  Yih-Leong Chang,et al.  Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. , 2012, Chest.

[6]  J. Dignam,et al.  The Use and Interpretation of Competing Risks Regression Models , 2012, Clinical Cancer Research.

[7]  Liyan Wan,et al.  Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  E. Brambilla,et al.  Insulin‐like growth factor‐1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma , 2011, The Journal of pathology.

[9]  C. Sima,et al.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens , 2011, Modern Pathology.

[10]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[11]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Humam Kadara,et al.  Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis , 2011, Clinical Cancer Research.

[13]  Akihiko Yoshizawa,et al.  A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors , 2010, The American journal of surgical pathology.

[14]  Mark A. Rubin,et al.  Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma , 2009, Journal of cellular and molecular medicine.

[15]  Kenji Suzuki,et al.  Bronchioloalveolar Carcinoma (Lepidic Growth) Component Is a More Useful Prognostic Factor than Lymph Node Metastasis , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  V. Capelozzi,et al.  Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. , 2009, Lung cancer.

[17]  G. Bepler,et al.  Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Meyerson,et al.  TTF1 expression in non‐small cell lung carcinoma: association with TTF1 gene amplification and improved survival , 2009, The Journal of pathology.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Lafitte,et al.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  V. Ninane,et al.  Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. , 2006, Lung cancer.

[22]  B. Chetaille,et al.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung , 2005, British Journal of Cancer.

[23]  J. Silverman,et al.  Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. , 2004, American journal of clinical pathology.

[24]  A Coldman,et al.  Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers , 2004, The Journal of pathology.

[25]  K. Kerr,et al.  Thyroid transcription factor 1 in pulmonary adenocarcinoma , 2004, Journal of Clinical Pathology.

[26]  N. Myong.  Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. , 2003, Journal of Korean medical science.

[27]  S. Wiseman,et al.  Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. , 2003, Human pathology.

[28]  P. Adegboyega,et al.  Immunohistochemical Study of Thyroid Transcription Factor-1 and HER2/ neu in Non–Small Cell Lung Cancer: Strong Thyroid Transcription Factor-1 Expression Predicts Better Survival , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  S. Lau,et al.  Expression of Thyroid Transcription Factor-1, Cytokeratin 7, and Cytokeratin 20 in Bronchioloalveolar Carcinomas: an Immunohistochemical Evaluation of 67 Cases , 2002, Modern Pathology.

[30]  G. Pelosi,et al.  Immunoreactivity for Thyroid Transcription Factor-1 in Stage I Non–Small Cell Carcinomas of the Lung , 2001, The American journal of surgical pathology.

[31]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[32]  F. Puglisi,et al.  Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[33]  J. Whitsett,et al.  Gene Structure and Expression of Human Thyroid Transcription Factor-1 in Respiratory Epithelial Cells (*) , 1995, The Journal of Biological Chemistry.

[34]  L. Tanoue.  Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .

[35]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[36]  J. Silverman,et al.  Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. , 2004, Human pathology.